Flares and Predicting Factors of Flares in Patients with Systemic Lupus Erythematosus Associated with Different Doses and Types of COVID-19 Vaccines DOI Creative Commons
Worawit Louthrenoo,

Punsita Tangkum,

Nuntana Kasitanon

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1399 - 1399

Опубликована: Дек. 12, 2024

Objectives: To compare disease activity and flares among different doses types of COVID-19 vaccines in systemic lupus erythematosus (SLE) patients. Methods: SLE patients a cohort, who received at least one dose vaccine (inactivated virus, adenovirus-vectored, or mRNA vaccines) between March October 2022 joined this study. The data regarding after each were reviewed compared. Results: Two hundred (524 total doses) included study, with 201, 199, 124 them receiving 1, 2, 3 vaccine, respectively, which comprised 183, 128, 213 inactivated vaccines, respectively. Regardless type, there no significant changes pre- post-vaccination. Flares significantly more common the 2nd 3rd than 1st (20.10% 17.74% vs. 8.96%, p = 0.001, 0.010, respectively), adenovirus-vectored vaccinations 11.48%, 14.84%, 17.84% (p ns), However, incidence rate flares/100 patient-months was not different. majority severe, renal being most frequent. Renal mucocutaneous involvement high prior to independent factors that predicted flares. Conclusions: vaccination uncommon. Most mainly due should have stable low order avoid

Язык: Английский

Flares and Predicting Factors of Flares in Patients with Systemic Lupus Erythematosus Associated with Different Doses and Types of COVID-19 Vaccines DOI Creative Commons
Worawit Louthrenoo,

Punsita Tangkum,

Nuntana Kasitanon

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1399 - 1399

Опубликована: Дек. 12, 2024

Objectives: To compare disease activity and flares among different doses types of COVID-19 vaccines in systemic lupus erythematosus (SLE) patients. Methods: SLE patients a cohort, who received at least one dose vaccine (inactivated virus, adenovirus-vectored, or mRNA vaccines) between March October 2022 joined this study. The data regarding after each were reviewed compared. Results: Two hundred (524 total doses) included study, with 201, 199, 124 them receiving 1, 2, 3 vaccine, respectively, which comprised 183, 128, 213 inactivated vaccines, respectively. Regardless type, there no significant changes pre- post-vaccination. Flares significantly more common the 2nd 3rd than 1st (20.10% 17.74% vs. 8.96%, p = 0.001, 0.010, respectively), adenovirus-vectored vaccinations 11.48%, 14.84%, 17.84% (p ns), However, incidence rate flares/100 patient-months was not different. majority severe, renal being most frequent. Renal mucocutaneous involvement high prior to independent factors that predicted flares. Conclusions: vaccination uncommon. Most mainly due should have stable low order avoid

Язык: Английский

Процитировано

1